Compare GSK plc (GSK) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs TKO Group Holdings Inc — how do they compare? GSK plc trades at $46.61 (market cap $91.88B), while TKO Group Holdings Inc trades at $178.96 (market cap $13.28B). The key difference: GSK plc is far larger — about 6.9× TKO Group Holdings Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and TKO Group Holdings Inc for 30 Days on average.
| GSK | TKO | |
|---|---|---|
Market Cap | $91.88B | $13.28B |
Volume | 7,730,529 | 857,653 |
Sector | Health | Media |
52-Week High | $61.18 | $224.96 |
52-Week Low | $43.24 | $175.58 |
Typical Hold Time | 93 Days | 30 Days |
Enterprise Value | $111.88B | $17.64B |
Dividend Yield | 3.9% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
TKO trades at $181.54, up 1.62% on the day, but technical indicators signal a bearish trend. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, and raised full-year guidance. Strong analyst sentiment persists with an 89% buy rating and a $227 consensus price target, suggesting significant upside. Recent news highlights media rights strength and a declared dividend.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but risks include execution on guidance and competitive pressures. The stock's high P/E of 63.73 indicates premium valuation, requiring sustained growth to justify. Near-term price action may be influenced by technical resistance and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
